Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from 3SBio ( (HK:1530) ) is now available.
3SBio, a biopharmaceutical company, has announced that its License Agreement with Pfizer for the PD-1/VEGF bispecific antibody (SSGJ-707) has come into effect, allowing Pfizer an exclusive option to develop and commercialize the product in China. Additionally, Pfizer has agreed to subscribe to new shares of 3SBio, representing a 1.28% stake post-issuance, at a discounted price, raising approximately HK$785.0 million for 3SBio.
The most recent analyst rating on (HK:1530) stock is a Hold with a HK$25.81 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
Average Trading Volume: 53,392,410
Technical Sentiment Signal: Buy
Current Market Cap: HK$68.51B
Learn more about 1530 stock on TipRanks’ Stock Analysis page.